

Abstract

Background: The COVID-19 pandemic had resulted in over 20.5 million confirmed cases and

175,000 deaths in England by December 2023. The pandemic's impact varied significantly across

different population groups, influenced by deprivation, ethnicity, and policy measures.

Methods: We analysed individual-level data on SARS-CoV-2 testing, hospitalisations, deaths, and

vaccination records in England from May 2020 to February 2022. We used Poisson regression models

to estimate incidence rate ratios (IRRs) for first pillar 2 PCR positive cases, associated

hospitalisations, and deaths, adjusting for sex, ethnicity, deprivation, geographic region, age, and

epidemiological week. Model selection was based on cross-validation and performance metrics (AIC,

R²).

Findings: The data analysed included 12,310,485 first SARS-CoV-2 pillar 2 PCR-confirmed

infections, 79,315 hospitalisations, and 107,823 deaths associated with the first SARS-CoV-2

infection. Significant differences were observed across IMD quintiles, with the most deprived areas

showing higher incidence rate ratios (IRRs) for death (1.64, 95% CI: 1.60-1.67) and hospitalisation

(1.80, 95% CI: 1.75-1.85) compared to the least deprived areas as the reference group for the entire

study period. Ethnic disparities were also notable, with higher IRRs for death and hospitalisation for

all non-White ethnicities relative to White ethnicities as the reference group. We note that the

magnitude of IRRs, for both deprivation and ethnicities, declined from the wild-type to the omicron

periods for severe outcomes. For cases, we observed IRRs above one for non-White ethnicities

during the wild-type and alpha periods only. Vaccine effectiveness (VE) was also assessed, with

models indicating a significant reduction in risk post-vaccination across all outcomes of interest.

Interpretation: Deprivation and ethnicity significantly influenced COVID-19 outcomes in England.

For severe outcomes, pre-existing health inequalities lead to large and persistent disparities. For

infections, both protective and support measures need to be structured with ethnicity and deprivation

in mind in the early parts of a pandemic.

 Funding: UK Medical Research Council, Schmidt Foundation, National Institute of Health Research, Community Jameel.

Keywords: SARS-CoV-2, risk factors, deprivation, ethnicity, vaccine effectiveness.

-
-
-

Research in Context

Evidence before this study

 The COVID-19 pandemic has significantly impacted global health, and previous research has highlighted the role of socioeconomic factors, such as deprivation and ethnicity, in influencing outcomes. McGowan et al. found in a scoping review that 91% of studies showed significantly higher COVID-19 mortality in areas of social disadvantage relative to more affluent areas. A systematic review by Pan et al. 2 showed the impact of ethnicity on clinical outcomes in COVID- 19. However, the impact of deprivation and ethnicity over different time periods of the COVID-19 pandemic and its interplay with public health measures is poorly understood.

Added value of this study

 This study leverages extensive data from multiple sources, including PCR-confirmed COVID-19 cases, hospitalisation records, death registries, and vaccination databases, to comprehensively analyse COVID-19 outcomes in relation to deprivation and ethnicity across England. Using Poisson regression, we provide estimates of incidence rate ratios (IRR) associated with different levels of deprivation and ethnic backgrounds. This study also incorporates data on periods defined by dominant variants and public health measures, allowing for a more detailed examination of how these factors interact with local socioeconomic contexts to influence health outcomes.

Implications of all the available evidence

 The findings underscore the importance of considering disparities in COVID-19 outcomes by deprivation and ethnicity and highlight the need for targeted strategies to address these inequalities. Policymakers should prioritise resource allocation and tailored interventions in high-risk areas to mitigate the adverse impacts of the pandemic. Furthermore, the effectiveness of vaccination programs should be continuously evaluated in the context of these socioeconomic determinants to enhance their efficacy and reach. This research contributes to the growing body of evidence supporting the need for an equitable public health response that addresses the specific needs of diverse populations across different localities before the pandemic by reducing health inequalities and in the pandemic response.

-
-
-
-
-
-
-

It is made available under a CC-BY 4.0 International license.

101 **Introduction**

- 102 By December 2023, the COVID-19 pandemic had caused over 20.5 million confirmed cases and over 103 175,000 deaths in England ^{3,4}. The pandemic did not impact individuals equally; individual-based 104 studies have explored the links between deprivation, ethnicity, and other factors on health outcomes to
- 105 varying levels $\frac{1,2,5-8}{2}$.

106 Past studies have explored heterogeneity in risk in England ⁹ and Scotland ¹⁰ using the Index of Multiple 107 Deprivation (IMD)¹¹ at the Lower-Tier Local Authority (LTLA) level. LTLAs are areas where local 108 government provides services, and the UK Office of National Statistics (ONS) provides an extensive 109 set of data, including population age distribution, ethnicity, and measures of deprivation. These 110 measures vary substantially across LTLAs, as did the number of infections, hospitalisations, and deaths 111 reported across England over the course of the pandemic (Figure 1). We aim to understand heterogeneity in COVID-19 outcomes and how this evolved to help inform policy planning ^{3,12,13}.

- 113 SARS-CoV-2 testing in England ¹⁴ had four "pillars": hospital testing for health and care workers and
- 114 individuals with clinical needs (pillar 1), freely available testing for the general population (pillar 2),
- serology (pillar 3) and targeted surveillance (pillar 4). Pillar 2 testing increased significantly from $10th$
- 116 May 2020, and most testing was halted on $27th$ February 2022 with the introduction of the 'Living with
- 117 COVID' strategy ¹⁵. Several public health measures were introduced over this period, including stay-
- 118 at-home orders (see SI B.5)^{3,13} at local and national levels.
- 119 We additionally investigate vaccine effectiveness (VE) in the post-vaccination period and the impact 120 of vaccination on risk heterogeneity. The SARS-CoV-2 immunisation programme in England was one 121 of the most rapid globally, with 89.9% of the adult population aged 20 or over receiving at least one 122 dose and 86.6% receiving at least two doses by 27th February 2022¹⁶. Test-negative case-control studies 123 (TNCCs) were the standard epidemiological tool for evaluating SARS-CoV-2 VE during the pandemic 17–19, though TNCCs can potentially suffer from biases ²⁰. The main alternative to TNCCs used for VE 125 estimation during the COVID-19 pandemic is large population observational cohort studies that use 126 individual-level healthcare and surveillance data linked to vaccination status 2^{1-24} .
- 127 128 [Figure 1] 129 130 131 132 133 134 135 136

Methods

Data sources

- The UK Health Security Agency (UKHSA) maintains a single unified database of all SARS-CoV-2
- positive test results in the country, categorised by pillar. The resulting database contains a hashed
- version of a unique identifier (NHS number), the age, sex, ethnic group, home LTLA, symptom status,
- testing pillar, and date of specimen for each positive case.
- Second, linked to the case database by (hashed) National Health Service (NHS) number, UKHSA
- maintains a database of all deaths within 28 days of a positive PCR test for SARS-CoV-2. This database
- records the date of death, the date of hospital admission, and how the death was identified (e.g., via
- hospital reporting, death registration, or both).
- Third, two NHS data sources on hospitalisation were also linked by NHS number to the case database:
- the Secondary Uses Service (SUS) data on hospital episodes and the Emergency Care Data Set (ECDS)
- on attendance at Accident and Emergency departments.
- Lastly, England maintains a national vaccination register, the National Immunisation Management
- 151 System (NIMS) ¹⁶. Every SARS-CoV-2 vaccine dose given in England is recorded at the time of vaccine
- administration. The anonymised version of the dataset used here contained a unique identifier (hashed
- NHS number), age, sex, ethnic group, LTLA and administration date.
- 154 We extracted data from the versions of these databases with data up to $25th$ July 2023. Cases with a valid NHS number were then linked to the NIMS vaccination dataset. Where a match was found, the case was classified as having received a vaccine (either before or after testing positive). Cases with no
- matching immunisation record were classified as having not been vaccinated.
- Population denominator data was used to calculate the number of people who have neither received a vaccine nor been diagnosed with SARS-CoV-2 infection. We used the 2021 Census population 160 estimates generated by the ONS 25 , stratified by age, sex and LTLA 26 . We made the simplifying assumption that in the absence of COVID-19, the size of the English population and its age distribution would have been at a steady state for our analysis period consistent with the Census 2021 estimates. Individuals with missing information on sex, age, or residence location were not included in the
- analysis.
- 165 We use the Index of Multiple Deprivation (IMD) dataset released in 2019¹¹ by the UK Ministry of Housing, Local Communities, and Local Government, aggregated at the LTLA level and its subcomponents (SI B.4).
-
-

It is made available under a CC-BY 4.0 International license.

Statistical Analysis

 Survival models were used to estimate Incidence Rate Ratios (IRR), an estimate of the increased risk of a particular outcome for a specific population group relative to a reference group. We used Poisson regression using an offset to adjust for person-days at risk to generate IRRs for the different strata of 174 interest, proving a good approximation to continuous time survival models (see SI A) 27 . Poisson regressions are more general than Cox proportional hazard survival models, allowing for non- proportional hazards. We investigated using negative binomial regressions to account for overdispersion. We parametrically captured variation by systematically examining evidence for interactions between covariates. We conducted model selection to identify the model which performed best across all three outcomes of interest (infection, hospitalisation, and deaths) by considering the 180 average Akaike's information criterion (AIC) and coefficient of determination $(R^2)^{28,29}$ across the three respective models.

 We included terms for sex, ethnic group, vaccination status and IMD in all models. We used a categorical IMD variable, ranking LTLAs by average IMD score and then binning them into quintiles (1 being least deprived, five being most). The three other covariates included in all models were geographic region (either upper tier local authority or region), age (in 10-year bands with the last band being 85+ or 10-year bands with all individuals below 40 grouped and a max-age of 80+) and epidemiological week. We examined all pairwise interactions between these three variables. The level of public health and social measures was computed from ONS LTLA restriction level data and the 189 Oxford COVID-19 Government Response Tracker³ and used as a parametric covariate (see SI Section A and C.4) as restriction levels changed several times, creating non-continuous time intervals.

 All survival analyses used the test specimen date as the outcome event date. Three SARS-CoV-2-related events were defined: death within 28 days of any positive PCR test, hospitalisation where the individual hospitalised tested PCR-positive between 14 days before admission and the day before discharge, and any PCR-confirmed infection within pillar 2. We only consider the first SARS-CoV-2 infection for all three events and associated hospitalisations and deaths.

 We fitted the model for all three outcomes of interest. Individuals were treated as censored after a positive SARS-CoV-2 pillar 2 PCR test to exclude post-primary infections and avoid bias since the UK

vaccination programme excluded people from being vaccinated within 28 days of a positive test.

Since the UKHSA/NHS and ONS data used different ethnicity categories, we aggregated ethnicities

into six groups that could be identified consistently across all datasets: White, South Asian, Asian

(other), Black, and Mixed/Other to be consistent across the two datasets (SI B.1). Details are provided

in Supplementary Information (SI B.1). The computation of age for each individual is outlined in the

SI B.2.

We estimated VE accounting for the type of vaccine (mRNA or adenovirus-based), time since

It is made available under a CC-BY 4.0 International license.

 vaccination, and outcome of interest (death, hospitalisation, Pillar 2 PCR positive case). Details are provided in SI section B.3. By comparing currently vaccinated individuals against people who would be vaccinated in the future, we controlled for potential differences in behaviour and exposure risk between those who are never vaccinated and those who eventually are. Censoring after the first recorded positive test partially mitigated estimates from being affected by the accumulation of naturally acquired immunity in the population. To investigate how estimates varied over time, for example, in periods dominated by particular variants, we restricted model fitting to data from the specific period of interest (censoring individuals with positive tests before that period).

- We used negative binomial regressions as a sensitivity analysis to explore over-dispersion in the count data. In all figures, we display only results with a p-value of 0.05 or less.
- All analyses were undertaken in R version 4.3.1 using the H2O.ai machine learning package version

 $3.42.0.2$ ³⁰, which offers high-performance parallelised algorithms for fitting general linear models to

large datasets. A 32-core Intel-based server with 128GB RAM was used to conduct the analyses.

Data access

While all data used in this analysis were anonymised, the individual-level nature of the data used risks

individuals being identified or being able to self-identify if it is released publicly. Requests for access

to the underlying source data should be directed to UKHSA.

Ethical approval

 Surveillance of COVID-19 testing and vaccination is undertaken under Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002 to collect confidential patient information [\(www.legislation.gov.uk/uksi/2002/1438/regulation/3/made](http://www.legislation.gov.uk/uksi/2002/1438/regulation/3/made)) under Sections 3(i) (a) to (c), 3(i)(d) (i)

and (ii) and 3(3). Data were shared with the investigators as part of the UK's emergency response to

- the COVID-19 pandemic via the SPI-M subcommittee of the UK Scientific Advisory Group for
- Emergencies (SAGE). Ethics permission was sought for the study via Imperial College London's
- standard ethical review processes, and the study was approved by the College's Research Governance
- and Integrity Team (ICREC reference: 21IC6945).

Role of the funding source

 The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

It is made available under a CC-BY 4.0 International license.

Results

- We present the breakdown of the England population (56,427,863 people in England [Census 2021],
- 56,417,353 are in our synthetic population, and 56,344,410 are included in the analysis) in Table 1,
- including the number of first episodes of SARS-CoV-2 infections (12,310,485) and associated
- hospitalisations (79,315) or deaths (107,823) linked to that first infection from the week beginning 10^{th}
- 244 May 2020 (isoweek 18) to $27th$ February 2022 (isoweek 8) confirmed by a pillar 2 PCR positive test.
- These 95 weeks cover the full period for which population-wide testing was available.
-

246 [Table 1]

- We examined a total of 360 model variants, which varied by the covariates and interactions included (see SI A.2 for covariate definitions considered): age, definition of deprivation, regional disaggregation, ethnicity disaggregation, and which interaction terms to include in the model. SI Table A.3–A.5 lists the top 88 selected models for each outcome of interest. We found that less granular age categories had better 10-fold cross-validation performance (under 40s, 10-year age bands up to 70, single group for 80+). Similarly, coarse spatial disaggregation (by NHS region of England) was favoured, and
- deprivation was quantified by IMD quintiles. We chose ethnicity disaggregation into six groups as the
- results were very close without a clear favoured disaggregation.
- We compared the estimates from the preferred model against the data, and found a good qualitative fit examining marginal IRRs (SI A.2).
- We investigated the impact of overdispersion for each outcome of interest using negative binomial regression models. For Pillar 2 PCR confirmed cases, we found a moderate level of overdispersion (k=0.33) during the wild-type period. We found that either very high values of k (indicating marginal overdispersion) or the Poisson model were preferred for all other periods. For hospitalisation and death outcomes, the Poisson model was always preferred (SI section A and Table A.1).
- Figure 2 presents the modelled IRRs for deprivation and ethnicity categories from the preferred model for each endpoint and by period defined by variant dominance. IRRs for sex, age and region are presented in SI Figure (D.12).
-

[Figure 2]

- When we consider the entire period (May 2020-February 2022), the highest IMD quintile, corresponding to the most deprived LTLAs, has an IRR (relative to the least deprived IMD quintile) of 1.64 (95% CI: 1.60-1.67) for death as the outcome, 1.80 (95% CI: 1.75-1.85) for hospitalisation, 1.02 (95% CI: 1.02-1.02) for a positive pillar 2 PCR test. For the Pillar 2 positive test outcome, we observed significant differences between periods defined by variant dominance. The biggest differences were observed for the Alpha variant with an IRR (for the highest quintile relative to the lowest) for that
- endpoint of 1.45 (95% CI: 1.45-1.46).

It is made available under a CC-BY 4.0 International license.

For deaths, over the entire study period, South Asian ethnicity had an IRR 1.63 (95% CI: 1.59-1.68),

- Asian (other) ethnicity an IRR 1.24 (95% CI: 1.17-1.32), and Black ethnicity an IRR 1.49 (95% CI:
- 1.43-1.54), with White ethnicity as the reference. For hospitalisation, over the entire study period, South
- Asian ethnicity had an IRR 1.90 (95% CI: 1.84-1.96), Asian (other) ethnicity an IRR 1.38 (95% CI:
- 1.30-1.47), and Black ethnicity an IRR 1.61 (95% CI: 1.55-1.68). Using pillar 2 PCR positive tests as
- the endpoint, over the entire study period, South Asian ethnicity had an IRR 0.89 (95% CI: 0.88-0.89),
- Asian (other) ethnicity an IRR 0.78 (95% CI: 0.78-0.79), and Black ethnicity an IRR 0.89 (95% CI:
- 0.89-0.90). The IRRs for Mixed/Other ethnicity are reported in SI Table D.3.
- Ethnicity differences declined for the Pillar 2 PCR positive test endpoint throughout the pandemic. IRR for pillar 2 PCR positive cases declines for all non-White ethnicities (relative to White) over time, with IRR_{WT} > IRR_{Alpha} > IRR_{Delta}. During the Omicron period, non-White IRRs were broadly similar to the 284 Delta period but typically slightly above IRR_{Delta}. For death and hospitalisation, we observed a declining 285 IRR over time for South Asian ethnicity, with IRR_{WT}, IRR_{Alpha}, and IRR_{Delta} exhibiting overlapping 286 confidence intervals but IRR_{Omicron} statistically significantly lower. Other Asian ethnicities had high IRRs (overlapping confidence intervals) for the WT and Alpha periods and significantly lower IRRs for Delta and Omicron. Black ethnicities exhibited high IRRs throughout the entire period in the range
- of 1.01-1.45 for death and 1.10-1.76 for hospitalisation.
- Results for deprivation were consistent for severe outcomes (hospitalisation and death) throughout the pandemic, with IRRs monotonically increasing as deprivation increased, but with IRRs during the Omicron period lower than other periods. This result also applied to a more granular representation of deprivation, using deciles (Figure D.12(A) in SI) and for the different subcomponents of the IMD measure (SI section E.1-E.7). For Pillar 2 PCR positive cases, we observed an increasing IRR with increasing deprivation for the WT and Alpha periods but not for the Delta and Omicron periods. This resulted in the IRR for the whole period being close to 1. This result was consistent with IMD deciles and the subcomponents of the IMD index.
-

298 [Figure 3]

- In Figure 4 we present the VE results (SI section B.3 and Table D.2). We obtain a VE (defined as 1- IRR) estimate for mRNA vaccines ranging from 86.8% (over 18 weeks after second dose, 95% CI: 86.2-87.3) to 97.1% (less than two weeks after booster dose, 95% CI: 96.6-97.6) for protection against death for individuals with at least two doses, 90.1% (over 18 weeks after second dose, 95% CI: 89.5- 90.5) to 96.7% (2-10 weeks after booster dose, 95% CI: 96.5-97) against hospitalisation and 30.4% (over 18 weeks after booster dose, 95% CI: 29.3-31.5) to 84.5% (2-10 weeks after second dose, 95% CI: 84.4-84.6) against pillar 2 PCR positive confirmed infections for the full study period.
- For adenovirus-based vaccines, we estimated VE for individuals with at least two doses, ranging from 77.2% (over 18 weeks after second dose, 95% CI: 76.2-78) to 95.9% (less than two weeks after booster

dose, 95% CI: 95.3-96.5) for protection against death, 84.3% (over 18 weeks after second dose, 95%

- CI: 83.6-85) to 96.2% (2-10 weeks after booster dose, 95% CI: 95.9-96.5) against hospitalisation, and
- 29.6% (over 18 weeks after booster dose, 95% CI: 27.6-31.5) to 68.5% (2-10 weeks after second dose,

95% CI: 68.3-68.6) against pillar 2 PCR-positive confirmed infections for the full study period.

 We found that VE was consistently lower for the Omicron period. There was little to no difference in VE estimates for severe outcomes for the Alpha and Delta time periods.

We present the estimated VE results for all variants, vaccine status, and vaccine types in SI Table D.2

with their associated 95% CIs. The confidence intervals are narrow due to the large number of events

- observed (Table 1B); confidence intervals are wider for the variant period-specific estimates.
-

[Figure 4]

 Figure 4 shows the estimated IRRs for the restriction level covariate. We estimated the IRR for the full time period of 1.14 (95% CI: 1.12-1.15) for deaths, 1.13 (95% CI: 1.12-1.15) for hospitalisation, and

1.17 (95% CI: 1.17-1.17) for Pillar 2 PCR positive cases. The estimated IRR for restriction level for the

WT and Alpha periods was lower for deaths and hospitalisation. However, for Pillar 2 PCR positive

cases, we found that the IRR for restriction level was higher during the WT period and lower for the

 Alpha period (Figure 4). The IRRs for the Delta period are one, as no substantial restrictions were in place at that time.

Discussion

 We considered the impact of sex, age, region, deprivation, level of restrictions, and ethnicity on the relative risk of a SARS-CoV-2 pillar 2 PCR-positive first infection, hospitalisation, or death. Our proposed model was selected to provide a good fit across all three outcomes of interest. Our results 330 extend previous work on the impact of deprivation ¹ and evidence risk heterogeneity by ethnicity in England $6-8$ and globally ².

- We find that modelling overdispersion for pillar 2 PCR positive cases was necessary for the wild-type 333 period, consistent with Morrissey et al. ¹², and the value for the overdispersion we find aligns with other 334 estimates outside China ^{31,32}. We did not find overdispersion to be present for severe outcomes, and the Poisson model provides the best fit to the data. Even though pillar 2 PCR tests were available widely, this indicates that some groups, defined by higher levels of deprivation or non-White ethnicity, may have accessed testing less, leading to the observed overdispersion. This was less likely to be the case for more severe outcomes as testing would be more likely conducted due to the more severe nature of the infection.
- The differences in IRRs we observe by outcome (infection, hospitalisation, or death) indicate a difference between severe outcomes and infections. For severe outcomes, we observed a significant

It is made available under a CC-BY 4.0 International license.

 risk heterogeneity by age, with older age groups at higher risks than younger age groups at an exponential rate (Figure SI D.10(B)) consistent with the variation of the infection fatality ratio by age 344 in the pre-vaccination era ³³. Increased risk is also positively associated with higher levels of deprivation (Figure 3A), and the difference between the most deprived quintile of LTLAs and the least deprived quintile is significant for all periods considered. Similarly, we find that non-White ethnicities are at increased risk. For pillar 2 PCR-positive cases, the picture is more nuanced. The risk by age is driven by contact patterns, as defined by the average number of contacts per person (SI Figure C.6) for the different age groups. We observed that the difference in risk between age groups was on a similar scale compared to the large differences we observed for severe outcomes. We saw similar risk heterogeneity patterns for both deprivation and ethnicity but less strongly than for severe outcomes. The results for 352 pillar 2 PCR-positive cases were consistent with other studies ³⁴ and that individuals exhibit self-353 protective behaviours ³⁵.

 For severe outcomes, we observed less variation throughout the pandemic, pointing to existing health inequalities driving the strong association between deprivation, ethnicity, and risk of severe outcomes. This held consistently for all sub-components of the index of multiple deprivation, except for the Living Environment component, and particularly strongly for the Income, Employment, Health, and Education sub-components (Figure SI sections E.1-E.7). This observation is consistent with known socio-359 economic and ethnic disparities in the UK for type-2 diabetes ³⁶, which is a known risk factor for SARS- CoV-2 infections. Interestingly, we observed a high IRR for South Asian ethnicity, for both severe outcomes and infections, which reduced over time (Figure 3.B), pointing to the metabolic component impacting outcomes being reduced for omicron and delta as individuals of South Asian ethnicity are at 363 higher risk of metabolic disease .

 We assessed vaccine effectiveness, and our results broadly align with previously published VE 365 estimates for England by UKHS A^{17} for similar periods and VE definitions. We find vaccine effectiveness for the mRNA vaccines is consistent with UKHSA estimates of 88.0% (95% CI: 85.3- 90.1) for two doses of BNT162b2 for infections for persons with the Delta variant. Similarly, we find vaccine effectiveness for the adenovirus vaccines is in line with UKHSA estimates of 67.0% (95% CI: 61.3-71.8) for persons with two doses of the ChAdOx1 nCoV-19 vaccine. For the Omicron variant, 370 estimates vary more widely³⁸ with VE against hospitalisation, ranging from 89.6% to 95.3 compared to 67.8% to 92.4% from the literature. Similarly, VE against pillar 2 PCR confirmed infection ranged from 17% to 69.5% compared to 11.7% to 75.3% in the literature. We note that we only consider first infections for the Omicron period, which may bias our VE estimates to be higher.

 The policy implications of our study are that both protective and support measures need to be structured with ethnicity and deprivation in mind, particularly in the early stages of a pandemic. Deprivation had a particularly significant impact during the Alpha variant era for infections, and for ethnicity, we observed a reduction of IRRs as the pandemic progressed (Figure 3). This suggests that more deprived

 areas were less able to isolate effectively, potentially due to work, during heightened restrictions. Ethnic minorities, in particular Bangladeshi and Pakistani men, worked in occupations directly impacted by lockdown measures, and more broadly, ethnic minorities had less access to savings 39 , potentially exposing them to a higher risk of community transmission.

 Considering different levels of restrictions, we found IRRs for infections and severe outcomes in the wild-type and Alpha periods to be above one. This highlights the impact of the different timing of restrictions between regions, as we already account for week and region effects in the model. We note that other results were not sensitive to whether restrictions were included as a predictor in the model.

- A limitation is that we only considered first infections in this study and could not make any statements
- about reinfections. However, we note that up to November 2021, with the arrival of the Omicron variant

of SARS-CoV-2, we have observed predominantly first infections. We only quantify the incidence

among those seeking tests, not the underlying infection incidence. This limits our ability to model the

impact of comorbidities, such as obesity⁴⁰, as we cannot differentiate if the outcome is worse due to

pre-existing comorbidities or those groups being more exposed.

Future research priorities include a multi-outcome survival model to incorporate infections and severe

- outcomes in the same model. Integrating serology and infection prevalence data is essential in
- addressing questions such as the impact of pre-existing comorbidities on the risk heterogeneity by
- ethnicity or socio-economic group.
-
-
-

Declarations

 Funding All authors acknowledge funding from the Medical Research Council (MRC) Centre for Global Infectious Disease Analysis (MR/X020258/1) funded by the UK MRC and carried out in the frame of the Global Health EDCTP3 Joint Undertaking supported by the EU; the NIHR for support for the Health Research Protection Unit in Modelling and Health Economics, a partnership between the UK Health Security Agency (UKHSA), Imperial College London, and London School of Hygiene & Tropical Medicine (grant code NIHR200908); a philanthropic donation from Community Jameel supporting the work of the Jameel Institute S.B. acknowledges support from the Novo Nordisk Foundation via The Novo Nordisk Young Investigator Award (NNF20OC0059309). SB acknowledges the Danish National Research Foundation (DNRF160) through the chair grant. S.B. acknowledges support from The Eric and Wendy Schmidt Fund for Strategic Innovation via the Schmidt Polymath Award (G-22-63345), which also supports C.M. The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. For the purpose of open access, the author has applied a 'Creative Commons Attribution' (CC BY) licence to any Author Accepted Manuscript version arising from this submission.

Availability of data and materials While all data used in this analysis were anonymised, the individual-level

nature of the data used risks individuals being identified or being able to self-identify if it is released publicly.

Requests for access to the underlying source data should be directed to UKHSA.

It is made available under a CC-BY 4.0 International license.

-
- **Code availability** https://github.com/cm401/covid19_risk_heterogeneity_england
- **Competing interests**. The authors declare no competing interests.

Authors' Contributions NMF, CM, and SB conceptualised the study. CM, WH, PPG, and NMF curated and

validated the data. CM formally analysed and visualised the data. SB and NMF acquired funding and supervised

- the study. CM wrote the original manuscript draft. All authors were responsible for the methodology and review
- and editing of the manuscript. All authors discussed, edited, and approved the final version of the manuscript. All
- authors had final responsibility for the decision to submit the manuscript for publication.
-
-

References

- 1 McGowan VJ, Bambra C. COVID-19 mortality and deprivation: pandemic, syndemic, and endemic health inequalities. *Lancet Public Health* 2022; **7**: e966–75.
- 2 Pan D, Sze S, Minhas JS, *et al.* The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. *EClinicalMedicine* 2020; **23**: 100404.
- 3 Hale T, Angrist N, Goldszmidt R, *et al.* A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). *Nat Hum Behav* 2021; **5**: 529–38.
- 4 Phillips T. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). https://github.com/OxCGRT/covid-policy-dataset.
- 5 Kontopantelis E, Mamas MA, Webb RT, *et al.* Excess deaths from COVID-19 and other causes by region, neighbourhood deprivation level and place of death during the first 30 weeks of the pandemic in England and Wales: A retrospective registry study. *Lancet Reg Health - Eur* 2021; **7**: 100144.
- 6 Ward H, Atchison C, Whitaker M, *et al.* SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. *Nat Commun* 2021; **12**: 905.
- 7 Lo C-H, Nguyen LH, Drew DA, *et al.* Race, ethnicity, community-level socioeconomic factors, and risk of COVID-19 in the United States and the United Kingdom. *eClinicalMedicine* 2021; **38**: 101029.
- 8 Mathur R, Rentsch CT, Morton CE, *et al.* Ethnic differences in SARS-CoV-2 infection and COVID- 19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. *The Lancet* 2021; **397**: 1711–24.
- 9 Padellini T, Jersakova R, Diggle PJ, *et al.* Time varying association between deprivation, ethnicity and SARS-CoV-2 infections in England: A population-based ecological study. *Lancet Reg Health - Eur* 2022; **15**: 100322.
- 10 Wood AJ, Sanchez AR, Bessell PR, Wightman R, Kao RR. Assessing the importance of demographic risk factors across two waves of SARS-CoV-2 using fine-scale case data. *PLOS Comput Biol* 2023; **19**: e1011611.
- 11 UK Ministry of Housing, Communities and Local Government. The English Indices of Deprivation 2019. 2019; published online Sept 26. https://assets.publishing.service.gov.uk/media/5d8e26f6ed915d5570c6cc55/IoD2019_Statistical_R elease.pdf.

- It is made available under a CC-BY 4.0 International license.
- 12 Morrissey K, Spooner F, Salter J, Shaddick G. Area level deprivation and monthly COVID-19 cases: The impact of government policy in England. *Soc Sci Med* 2021; **289**: 114413.
- 13 Phillips T. Oxford Covid-19 Government Response Tracker (OxCGRT), Blavatnik School of Government, University of Oxford. https://github.com/OxCGRT/covid-policy-tracker.
- 14 Department of Health and Social Care. Coronavirus (COVID-19): scaling up testing programmes. 2020 https://assets.publishing.service.gov.uk/media/5e888f05e90e0707799498b3/coronavirus-covid-19-testing-strategy.pdf.
- 15 UK Health Security Agency. Testing Times: striving for quality in the COVID-19 national testing service, April 2020 to March 2022. https://www.gov.uk/government/publications/coronavirus-covid-19-scaling-up-testing-programmes.
- 16 NHS England. National vaccination programmes. https://www.england.nhs.uk/contact-us/privacy-notice/national-flu-vaccination-programme/.
- 17 Lopez Bernal J, Andrews N, Gower C, *et al.* Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med* 2021; **385**: 585–94.
- 18 Lopez Bernal J, Andrews N, Gower C, *et al.* Effectiveness of the Pfizer-BioNTech and Oxford- AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *BMJ* 2021; : n1088.
- 19 Chua H, Feng S, Lewnard JA, *et al.* The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology. *Epidemiology* 2020; **31**: 43–64.
- 20 WHO. Evaluation of COVID-19 vaccine effectiveness: interim guidance, 17 March 2021. 2021 https://iris.who.int/handle/10665/340301.
- 21 Bar-On YM, Goldberg Y, Mandel M, *et al.* Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. *N Engl J Med* 2021; **385**: 1393–400.
- 22 Chemaitelly H, Yassine HM, Benslimane FM, *et al.* mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nat Med* 2021; **27**: 1614–21.
- 23 Vasileiou E, Simpson CR, Shi T, *et al.* Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *The Lancet* 2021; **397**: 1646–57.
- 24 Nafilyan V, Bermingham CR, Ward IL, *et al.* Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England. *Nat Commun* 2023; **14**: 1541.
- 25 ONS. Census. https://www.ons.gov.uk/census.
- 26 Office of National Statistics. Office of National Statistics Census 2021 Create a custom dataset. https://www.ons.gov.uk/datasets/create.
- 27 Laird N, Olivier D. Covariance Analysis of Censored Survival Data Using Log-Linear Analysis Techniques. *J Am Stat Assoc* 1981; **76**: 231–40.
- 28 Stoica P, Selen Y. Model-order selection. *IEEE Signal Process Mag* 2004; **21**: 36–47.
- 29 Kvalseth TO. Cautionary Note about R 2. *Am Stat* 1985; **39**: 279.

- 30 H2O. H2O.ai. h2o: R Interface for H2O. R package version 3.42.0.2 2023. https://github.com/h2oai/h2o-3.
- 31 Endo A, Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group, Abbott S, Kucharski AJ, Funk S. Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China. *Wellcome Open Res* 2020; **5**: 67.
- 32 Hodcroft EB, Wohlfender MS, Neher RA, Riou J, Althaus CL. Estimating *R ^e* and overdispersion in secondary cases from the size of identical sequence clusters of SARS-CoV-2. 2024; published online May 27. DOI:10.1101/2024.05.26.24307940.
- 33 COVID-19 Forecasting Team. Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. *The Lancet* 2022; **399**: 1469–88.
- 34 Rawson T, Hinsley W, Sonabend R, Semenova E, Cori A, Ferguson NM. The impact of health inequity on spatial variation of COVID-19 transmission in England. *PLOS Comput Biol* 2024; **20**: e1012141.
- 35 Papageorge NW, Zahn MV, Belot M, *et al.* Socio-demographic factors associated with self-protecting behavior during the Covid-19 pandemic. *J Popul Econ* 2021; **34**: 691–738.

 36 Nagar SD, Nápoles AM, Jordan IK, Mariño-Ramírez L. Socioeconomic deprivation and genetic ancestry interact to modify type 2 diabetes ethnic disparities in the United Kingdom. *eClinicalMedicine* 2021; **37**: 100960.

- 37 Ramachandran A. Trends in prevalence of diabetes in Asian countries. *World J Diabetes* 2012; **3**: 110.
- 38 Stowe J, Andrews N, Kirsebom F, Ramsay M, Bernal JL. Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study. *Nat Commun* 2022; **13**: 5736.
- 39 Platt L, Warwick R. COVID‐19 and Ethnic Inequalities in England and Wales * . *Fisc Stud* 2020; **41**: 259–89.
- 40 Yates T, Summerfield A, Razieh C, *et al.* A population-based cohort study of obesity, ethnicity and COVID-19 mortality in 12.6 million adults in England. *Nat Commun* 2022; **13**: 624.
-
-

-
-
-
-

It is made available under a CC-BY 4.0 International license.

It is made available under a CC-BY 4.0 International license.

532 **A**

533 534

535 **B**

536 537

538 **Table 1: Population for England with numbers of first Pillar 2 PCR confirmed SARS-CoV-2, hospitalisations and**

539 **deaths between 10th May 2020 and 27th February 2022. (A) Population breakdown by sex, age, region, deprivation,**

540 **and ethnicity. (B) Breakdown by vaccination status for categories with more than 200,000 doses at the end of the**

541 **study period (n is the count of individuals in this category at the end of the study period, person days at risk and**

542 **counts of Pillar 2 PCR positive cases, hospitalisations and deaths are over the entire study period). Vaccination status**

543 **categories are by vaccination type (Adenovirus or mRNA), vaccine dose, and time since vaccination. The whole table** 544 **for panel B is available in SI Figure D.9.**

It is made available under a CC-BY 4.0 International license.

 Figure 2: Estimated IRRs for (A) deprivation and (B) ethnicity covariates from preferred models. Deprivation was categorised by quintiles of the Index of Multiple Deprivation score defined at the LTLA level (results for sub- components are available in the SI), with the first (least deprived) quintile (IMD1) being the reference group (IRR=1). Results are shown for the whole pandemic ('all' - test dates between May 2020 and February 2022) and for the time intervals within that period where specific viral variants dominated (see SI for details). WT=Wild-Type (pre-December 2020).

 Figure 3: Vaccine effectiveness (VE=1-RR) for different vaccination statuses with not vaccinated as the reference group (IRR=1 / VE=0). Results are shown for the whole pandemic ('all' - test dates between May 2020 and February

 2022) and for the time intervals within that period where specific viral variants dominated (see SI for details). Results for the Second Dose and Booster Dose categories are displayed for mRNA and Adenovirus vaccines (all other results

are in SI Table D.3 and Figure D.11). WT=Wild-Type (pre-December 2020).

It is made available under a CC-BY 4.0 International license.

 Figure 4: Estimated IRRs for restriction levels. Results are shown for the whole pandemic ('all' - test dates between May 2020 and February 2022) and for the time intervals within that period where specific viral variants dominated (see SI for details). Restriction level is a numeric covariate in the model.